No Data
No Data
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $990
FDA 'Three Reflections' removed eli lilly and co (LLY.US) weight loss drug from the shortage list, Hims & Hers Health (HIMS.US) promptly rose by 10%.
After the FDA decided to remove Eli Lilly and Co's tirzepatide from the list of pharmaceutical shortages, a lawsuit related to this delisting caused Hims & Hers Health (HIMS.US) to rise on Monday, closing up about 10%.
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Hims +6% Monday After FDA Said it Might Halt Hims Weight Loss Drug Sales Friday
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
No Data
No Data
protraderx : institutionscselling into strength